Phase 2 study of DZD8586, a non-covalent BBB penetrant LYN/BTK dual inhibitor, as monotherapy in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL; TAI-SHAN9).

Authors: Lugui Qiu, Yajun Li, Keshu Zhou, Ming Jiang, Wei Liu, Zhiming Li, Meifang Zheng, Zengjun Li, Wenbin Qian, Mei Lan, Pengcheng He, Kaiyang Ding, Fang Zhu, Hongmei Jing, Ziyi Liu, Lihua Qiu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e19050

Source: Full article

---

Abstract

e19050